Document:

EX-10.2

 EXHIBIT 10.2 

SECURITY AGREEMENT 
 This
Security Agreement (this “Agreement”) is made March 3, 2015 by and among Bioject Medical Technologies Inc. (the “Company”) and its wholly owned subsidiary Bioject Inc. (the “Subsidiary”), each an Oregon
corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 (collectively, the “Grantors”), and Mark A. Logomasini & Associates, Inc. SEP Fund, the holder of the Company’s Senior Secured Bridge
Promissory Note aggregating $116,636 dated March 3, 2015 (the “Note”) and with the address set forth on the signature page hereto (the “Noteholder”). 

RECITALS 
 The Noteholder has agreed to
make a secured loan to the Company, evidenced by the Note, and secured by all the accounts receivable from Ferring Pharmaceuticals to the Company, whether presently existing or hereafter acquired. 

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged and intending to be legally bound, as
collateral security for the prompt and complete payment when due of the Note, Grantors hereby represent, warrant, covenant and agree as follows: 

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantors’
present or future obligations under the Note, Grantors hereby grants a security interest in all of Grantors’ right, title and interest in, to and under its registered and unregistered rights in the all the accounts receivable from Ferring
Pharmaceuticals to the Company, (all of which shall collectively be called the “Collateral”), including, without limitation, all proceeds of the foregoing. 

2. Covenants and Warranties. Grantors represents, warrants, covenants and agrees as follows: 

 

	 	(a)	Grantors are the sole owners of the Collateral;

  

	 	(b)	Performance of this Agreement does not conflict with or result in a breach of any material agreement to which Grantors are bound; 

  

	 	(c)	During the term of this Agreement, Grantors will not transfer or otherwise encumber any interest in the Collateral. 

  

	 	(d)	To their knowledge, all of the Collateral is valid and enforceable, and no part of the Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made in writing that any part of the
Collateral violates the rights of any third party;

  

	 	(e)	Grantors shall protect, defend and maintain the validity and enforceability of the Collateral; 

  

	 	(f)	Grantors shall take such further actions as Noteholder may reasonably request from time to time to perfect or continue the perfection of Noteholder’s interest in the Collateral; 

 

	 	(g)	This Agreement creates, and in the case of after acquired Collateral this Agreement will create, at the time Grantors first have rights in such after acquired Collateral and Noteholder have taken all actions required
for perfection, in favor of Noteholder, a valid and perfected first priority security interest and collateral assignment in the Collateral in the United States securing the payment and performance of the obligations evidenced by the Note;

  

	 	(h)	To its knowledge, except for, and upon, the filing of UCC financing statements, or other notice filings or notations in appropriate filing offices, if necessary to perfect the security interests created hereunder, no
authorization, approval or other action by, and no notice to or filing with, any U.S. governmental authority or U.S. regulatory body is required either (a) for the grant by Grantors of the security interest granted hereby, or for the execution,
delivery or performance of this Agreement by Grantors in the U.S. or (b) for the perfection in the United States or the exercise by Noteholder of its rights and remedies thereunder; 

  
 1 

	 	(i)	All information heretofore, herein or hereafter supplied to Noteholder by or on behalf of Grantors with respect to the Collateral is true and correct in all material respects; and 

 

	 	(j)	Grantors shall not enter into any agreement that would materially impair or conflict with Grantors’ obligations hereunder without Noteholder’s prior written consent, which consent shall not be unreasonably
withheld. Except as permitted under the Note, Grantors shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantors’
rights and interest in any property included within the definition of the Collateral acquired under such contracts. 

 4.
Noteholder’s Rights. Noteholder shall have the right, but not the obligation, to take, at Grantors’ sole expense, any actions that Grantors is required under this Agreement to take but which Grantors fails to timely take, after
fifteen (15) days’ notice to Grantors. Grantors shall reimburse and indemnify Noteholder for all reasonable costs and reasonable expenses incurred in the reasonable exercise of its rights under this section 4. 

5. Further Assurances; Attorney in Fact. 

(a) On a continuing basis, Grantors will, upon reasonable request by Noteholder, subject to any prior licenses, encumbrances and
restrictions and prospective licenses, make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and
collateral agreement, and take all such action as may reasonably be requested by Noteholder, to perfect Noteholder’s security interest in the Collateral and otherwise to carry out the intent and purposes of this Agreement, or for assuring and
confirming to Noteholder the grant or perfection of a security interest in all Collateral. 
 (b) Grantors appoint Noteholder as
Grantors’ attorney-in-fact, with full authority in the place and stead of Grantors and in the name of Grantors, Noteholder or otherwise, from time to time in Noteholder’s discretion, upon Grantors’ failure or inability to do so, to
take any action and to execute any instrument which Noteholder may deem reasonably necessary or advisable to accomplish the purposes of this Agreement, including, to file, in its sole discretion, one or more financing or continuation statements and
amendments thereto, or other notice filings or notations in appropriate filing offices, relative to any of the Collateral, without notice to Grantors, with all appropriate jurisdictions, as Noteholder deem appropriate, in order to perfect or protect
Noteholder’s interest in the Collateral. 
 6. Events of Default. The occurrence of an Event of Default under the Note
shall constitute an Event of Default under this Agreement. 
 7. Remedies. Upon the occurrence and during the continuance of an
Event of Default, Noteholder shall have the right to exercise all the remedies of a secured party under the Oregon Uniform Commercial Code. Grantors will pay any expenses (including reasonable attorney’s fees) incurred by Noteholder in
connection with the exercise of any of Noteholder’s rights hereunder, including without limitation any expense incurred in disposing of the Collateral in accordance with the terms hereof. All of Noteholder’s rights and remedies with
respect to the Collateral shall be cumulative. 
 8. Indemnity. Grantors agree to defend, indemnify and hold harmless Noteholder
and its agents (each an “Indemnified Person”) against: (a) all obligations, demands, claims, and liabilities (collectively, “Claims”) claimed or asserted by any other party in connection with the transactions contemplated by
this Agreement, and (b) all losses or expenses in any way suffered, incurred, or paid by Noteholder as a result of or in any way arising out of, following or consequential to transactions between Noteholder and Grantors, under this Agreement
(including without limitation, reasonable attorney’s fees and reasonable expenses), except for Claims and/or losses arising from or out of an Indemnified Person’s gross negligence or willful misconduct. 

9. Termination. At such time as Grantors shall completely repay the Note and any other obligations under the Note, secured
hereunder, Noteholder shall execute and deliver to Grantors all releases, terminations, and other instruments as may be necessary or proper to release the security interest hereunder. 

  
 2 

 10. Course of Dealing. No course of dealing, nor any failure to exercise, nor any delay in
exercising any right, power or privilege hereunder shall operate as a waiver thereof. 
 11. Amendments. This Agreement may be
amended only by a written instrument signed by both parties hereto. 
 12. Counterparts. This Agreement may be executed in two
or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument. 

13. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California. 

GRANTORS AND NOTEHOLDER EACH HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF
ANY OF THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS. EACH PARTY RECOGNIZES AND AGREES THAT THE FOREGOING WAIVER
CONSTITUTES A MATERIAL INDUCEMENT FOR IT TO ENTER INTO THIS AGREEMENT. EACH PARTY REPRESENTS AND WARRANTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING
CONSULTATION WITH LEGAL COUNSEL. 
 14. Confidentiality. In handling any confidential information, Noteholder shall exercise the
same degree of care that they exercise for their own proprietary information, but disclosure of information may be made: (i) to Noteholder or affiliates in connection with their present or prospective business relations with Grantors;
(ii) to prospective transferees or purchasers of any interest in the Note (provided, however, Noteholder shall use commercially reasonable efforts to obtain such prospective transferee’s or purchaser’s agreement to the terms of
this provision); (iii) as required by law, regulation, subpoena, or other order, (iv) as required in connection with Noteholder’s examination or audit; and (v) as Noteholder consider appropriate in exercising remedies under
this Agreement. Confidential information does not include information that either: (a) is in the public domain or in Noteholder’s possession when disclosed to Noteholder, or becomes part of the public domain after disclosure to Noteholder
through no fault of Noteholder; or (b) is disclosed to Noteholder by a third party, if Noteholder reasonably do not know that the third party is prohibited from disclosing the information. 

Agreed, as of the date first set forth above: 
 Grantors:

  

			
	Bioject Medical Technologies Inc.
		
	By:		 /s/ Tony K. Chow

	Name:		Tony K. Chow
	Title:		President and Chief Executive Officer
	
	Bioject Inc.
		
	By:		 /s/ Tony K. Chow

	Name:		Tony K. Chow
	Title:		President and Chief Executive Officer
	
	Mark A Logomasini & Associates, Inc. SEP Fund
	
	 /s/ Mark A.
Logomasini            

	Address: 26212 Dimension Drive, Suite 260, Lake Forest, CA 92630

  
 3EX-10.3

 EXHIBIT 10.3 

SENIOR BRIDGE PROMISSORY NOTE 

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND HAS BEEN ACQUIRED WITHOUT A VIEW TO
DISTRIBUTION AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE NOTE UNDER THE ACT AND UNDER ANY APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL FOR THE HOLDER
(CONCURRED IN BY LEGAL COUNSEL FOR THE CORPORATION) THAT SUCH REGISTRATION IS NOT REQUIRED AS TO SUCH SALE OR OFFER 
  

			
	$50,000.00		Date: September 22, 2014

 For value received, Bioject Medical
Technologies Inc., an Oregon corporation (the “Company”), promises to pay to John E. Anderson (the “Holder”) the principal sum of Fifty thousand dollars ($50,000.00), together with interest thereon as set forth herein (this
“Note”). 
 The following is a statement of the rights of the Holder and the conditions to which this Note is subject, and to
which the Holder, by the acceptance of this Note, agrees: 
  

	1.	Payment Terms and Security. The unpaid principal balance from time to time outstanding under this Note shall bear interest at the rate of 24% per annum. The outstanding principal balance of and accrued but
unpaid interest under this Note shall be repaid by the Company on or before December 31, 2014 (the “Maturity Date”) unless prepaid or extended pursuant to the terms hereof. Except as otherwise provided herein, both principal and
interest shall be payable on the Maturity Date in lawful money of the United States of America to the Holder at the address listed on the signature page hereto (or at such other location as shall be designated by the Holder in a written notice to
the Company), in same day funds. 

 Optional Conversion: At Holder’s option, prior to repayment of this note and accrued
interest is convertible to Bioject Medical Technologies Inc. Series I Convertible Preferred Stock at a price of $10 per share. 
  

	2.	Events of Default. If any of the events specified in this Section 2 shall occur (herein individually referred to as an “Event of Default”), the Holder of the Note may, so long as such condition
exists, declare the entire principal and unpaid accrued interest hereon immediately due and payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived: 

 

	 	(a)	Default in the payment of the principal and unpaid accrued interest of this Note when due and payable if such default is not cured by the Company within ten (10) business days after the Holder has given the Company
written notice of such default; or 

  
 1 

	 	(b)	Any breach by the Company of any representation, warranty, or covenant in this Note; provided, that, in the event of any such breach, to the extent such breach is susceptible to cure, such breach shall not have been
cured by the Company within ten (10) business days after written notice to the Company of such breach; or 

  

	 	(c)	The Company shall (i) apply for or consent to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property, (ii) make a general assignment for the
benefit of its or any of its creditors, (iii) be dissolved or liquidated in full or in part, (iv) commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts
under any bankruptcy, insolvency or other similar law now or hereafter in effect or consent to any such relief or to the appointment of or taking possession of its property by any official in an involuntary case or other proceeding commenced against
it or (v) take any action for the purpose of effecting any of the foregoing; or 

  

	 	(d)	Proceedings for the appointment of a receiver, trustee, liquidator or custodian of the Company or of all or a substantial part of the property thereof, or an involuntary case or other proceedings seeking liquidation,
reorganization or other relief with respect to the Company or the debts thereof under any bankruptcy, insolvency or other similar law now or hereafter in effect shall be commenced and an order for relief entered, or such case or proceeding shall not
be dismissed, discharged or stayed within 60 days of commencement. 

 Notwithstanding anything to the contrary contained
herein, if any of the events described in Sections 2(c) or (d) occur, this Note shall be automatically accelerated and the entire principal and unpaid accrued interest thereon shall immediately become due and payable without presentment,
demand, protest or any other notice of any kind, all of which are hereby expressly waived. 
  

	3.	Mandatory Prepayment. Prior to the Maturity Date, this Note will be prepaid if the Company can do so but still have adequate cash to fund its ongoing operations for then for seeable future. 

 

	4.	Assignment. The rights and obligations of the Company and the Holder of this Note shall be binding upon and benefit the successors, assigns, heirs, administrators and transferees of the parties.

  

	5.	Waiver and Amendment. Any provision of this Note may be amended, waived or modified upon the written consent of the Company and the Holder. No waiver by any party of any default, misrepresentation, or breach of
warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any way any rights arising because of any prior or
subsequent such occurrence. 

  

	6.	 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given (a) upon
personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile (provided that notice is also given under clause (c) below) if 

  
 2 

	 	
sent during normal business hours of the recipient; if not sent during normal business hours of the recipient, then on the next business day, or (c) upon receipt by the party to be notified
by nationally recognized overnight courier service. All communications shall be sent to the party at the address as set forth herein or at such other address as such party may designate by ten (10) days advance written notice to the other party
hereto. 

  

	7.	Governing Law; Waiver of Jury Trial. This Note shall be governed by and construed in accordance with the laws of the state of California, exclusive of conflicts of law provisions. In the event of any dispute
between the parties to this Note, the parties agree that the dispute shall be settled in the state or federal courts located in the County of Washington in the State of Oregon. The parties hereto waive all right to trial by jury in any action or
proceeding to enforce or defend any rights under this Note. 

  

	8.	Heading; References. All headings used herein are used for convenience only and shall not be used to construe or interpret this Note. Except where otherwise indicated, all references herein to Sections refer to
Sections hereof. 

 IN WITNESS WHEREOF, each of the Company has executed this Senior Secured Bridge Promissory Note as of the
date first above written. 
  

			
	HOLDER
		
	By		 /s/ John E. Anderson

	Name:		John E. Anderson
	
	BIOJECT MEDICAL TECHNOLOGIES INC.
		
	By		 /s/ Mark Logomasini

	Name:		Mark Logomasini
	Title:		President and Chief Executive Officer

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]